NCCN Awards Three Research Grants to Advance Gastrointestinal Cancer Treatments with Taiho Oncology
Key Insights
The National Comprehensive Cancer Network (search) has awarded three research grants to investigate tipiracil/trifluridine (search) and futibatinib in gastrointestinal cancers, funded through collaboration with Taiho Oncology (search), Inc.
Selected research projects will explore novel treatment combinations including TAS-102 with PARP (search) inhibition for pancreatic cancer, futibatinib with paclitaxel/ramucirumab for gastroesophageal cancer (search), and trifluridine/tipiracil plus oxaliplatin for biliary tract cancer (search).
The two-year research initiative aims to address significant unmet needs in gastrointestinal cancer (search) treatment, particularly focusing on advanced-stage patients with limited therapeutic options.
The National Comprehensive Cancer Network (search) (NCCN) Oncology Research Program has launched a new research initiative to advance treatment options for gastrointestinal cancers, supported by funding from Taiho Oncology (search), Inc. The program has awarded three grants to investigate innovative applications of tipiracil/trifluridine (search) (FTD/TPI) and futibatinib in treating various gastrointestinal malignancies.
Selected Research Projects
Three distinguished research teams have been chosen to lead potentially groundbreaking studies:
Dr. Madison Conces from Case Comprehensive Cancer Center will investigate the combination of trifluridine/tipiracil with oxaliplatin in advanced or metastatic biliary tract cancer (search) patients who have progressed after first-line therapy.
At Roswell Park Comprehensive Cancer Center, Dr. Christos Fountzilas will explore the potential of TAS-102 combined with PARP (search) inhibition as a maintenance treatment specifically for advanced pancreatic ductal adenocarcinoma (search) patients with TP53 (search) mutations.
Dr. Chengwei Peng of the Robert H. Lurie Comprehensive Cancer Center will conduct a Phase I dose escalation trial examining futibatinib in combination with paclitaxel/ramucirumab for second-line treatment of gastroesophageal cancer (search).
Addressing Critical Treatment Gaps
Gastrointestinal cancers remain a significant global health challenge, with colorectal and gastric cancers ranking among the most prevalent malignancies worldwide. Despite recent therapeutic advances, patients with advanced disease often face limited treatment options, highlighting the urgent need for innovative approaches.
"Innovative research is essential for driving progress in cancer care," stated Dr. Crystal S. Denlinger, Chief Executive Officer of NCCN. "We are proud to support these investigators as they explore new ways to potentially improve outcomes for patients with gastrointestinal cancers."
Research Implementation and Oversight
The selected projects underwent rigorous peer review by a Scientific Review Committee comprising leading oncology experts from NCCN Member Institutions. Each study is scheduled for completion within a two-year timeframe.
Dr. Tehseen Salimi, Senior Vice President and Head of Medical Affairs at Taiho Oncology (search), emphasized the importance of external research: "We strive to improve the lives of patients with cancer, their families and their caregivers. We are pleased to support the NCCN Oncology Research Program in their important mission to foster innovation and knowledge discovery."
The research initiative represents a significant step forward in the ongoing effort to develop more effective treatment strategies for gastrointestinal cancers, potentially opening new therapeutic avenues for patients with limited options.